|Print Page Close Window|
BeiGene, Ltd. (“BeiGene”) is a commercial-stage biotechnology company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer.
BeiGene has a broad portfolio consisting of six internally-developed, clinical-stage, drug candidates, including three late-stage clinical drug candidates, zanubrutinib (BTK inhibitor), tisle...more >
BGNE (American Depositary Shares)
12/14/18 4:00 p.m. ET
Currency is USD
There are currently no events scheduled.
Sign up to receive e-mail alerts
© 2016 BeiGene. All Rights Reserved.